Astellas Pharma Inc. co-promotes telmisartan subjugate than the trademark Micardis®, Bayer HealthCare promote telmisartan under the lampoon christen Kinzalmono®, Kinzalkomb® (combination beside hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) delimited by marketplace across Europe. Pritor®, and PritorPlus® be also market by money matter of GlaxoSmithKline in elected markets.
The promoter of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected region be Bayer HealthCare and GlaxoSmithKline.
Boehringer Ingelheim The Boehringer Ingelheim pairing is one of the world's 20 major pharmaceutical firm. Headquartered in Ingelheim, Germany, it operate worldwide with 135 affiliate in 47 countries and 39,800 human treasures. Since it be found in 1885, the family-owned company have be committed to research, surfacing, trade and marketing advanced products of illustrious beneficial good tine in favour of human and veterinary pills.
In 2007, Boehringer Ingelheim mail fencing public sale of 10.9 billion euro while overheads one fifth of net sales in its largest company segment Prescription Medicines by the players of research and change for the better.
Related links: Boehringer Ingelheim grit pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals in the unseal air the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular measures in high-risk patients callous to angiotensin-converting enzyme inhibitors: a randomized controlled try-out. Lancet Published online 31 August 2008.
2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high hazard for vascular events. N Eng J Med 2008; 358(15):1547-59.
4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychotherapy. A examination of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.
5.Matchar DB, et al. Systematic Review: Comparative value of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for overstatement halcyon days hypertension.
Ann Intern Med 2008; 148:16-29.
6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A extensive review of mortality and disability from bug, gash, and risk factor in 1990 and projected to 2020.
Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.
